Let’s look at the key reasons that are pushing Ultragenyx Pharmaceutical Inc. (RARE) to new highs

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) kicked off on January 24, 2023, at the price of $42.84, up 1.59% from the previous trading day. During the day, the shares moved up to $43.5699 and dropped to $42.51 before settling in for the closing price of $42.81. Over the past 52 weeks, RARE has traded in a range of $33.36-$85.53.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


During the last 5-year period, the sales growth of Healthcare Sector giant was 383.50%. While this was happening, its average annual earnings per share was recorded -118.40%. With a float of $66.65 million, this company’s outstanding shares have now reached $70.05 million.

Let’s determine the extent of company efficiency that accounts for 1119 employees. In terms of profitability, gross margin is +91.68, operating margin of -108.63, and the pretax margin is -128.91.

Ultragenyx Pharmaceutical Inc. (RARE) Breakdown of a Key Holders of the stock

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ultragenyx Pharmaceutical Inc. is 0.40%, while institutional ownership is 97.80%. The most recent insider transaction that took place on Dec 30, was worth 892,352. In this transaction President & CEO of this company sold 19,582 shares at a rate of $45.57, taking the stock ownership to the 541,108 shares. Before that another transaction happened on Dec 21, when Company’s SVP, Chief Accounting Officer sold 2,031 for $43.96, making the entire transaction worth $89,283. This insider now owns 16,197 shares in total.

Ultragenyx Pharmaceutical Inc. (RARE) Recent Fiscal highlights

In the latest quarterly report, which was put into the public domain on 6/29/2022, the organization reported -$2.26 earnings per share (EPS), lower than consensus estimate (set at -$1.75) by -$0.51. This company achieved a net margin of -129.20 while generating a return on equity of -43.72. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.86 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -118.40% per share during the next fiscal year.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Trading Performance Indicators

Take a look at Ultragenyx Pharmaceutical Inc.’s (RARE) current performance indicators. Last quarter, stock had a quick ratio of 4.40. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.69.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -9.74, a number that is poised to hit -2.12 in the next quarter and is forecasted to reach -7.72 in one year’s time.

Technical Analysis of Ultragenyx Pharmaceutical Inc. (RARE)

Looking closely at Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), its last 5-days average volume was 0.74 million, which is a jump from its year-to-date volume of 0.72 million. As of the previous 9 days, the stock’s Stochastic %D was 57.02%. Additionally, its Average True Range was 2.24.

During the past 100 days, Ultragenyx Pharmaceutical Inc.’s (RARE) raw stochastic average was set at 59.82%, which indicates a significant increase from 46.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.33% in the past 14 days, which was higher than the 58.20% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $41.02, while its 200-day Moving Average is $49.59. However, in the short run, Ultragenyx Pharmaceutical Inc.’s stock first resistance to watch stands at $43.87. Second resistance stands at $44.25. The third major resistance level sits at $44.93. If the price goes on to break the first support level at $42.81, it is likely to go to the next support level at $42.13. Now, if the price goes above the second support level, the third support stands at $41.75.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Key Stats

The company with the Market Capitalisation of 2.98 billion has total of 70,106K Shares Outstanding. Its annual sales at the moment are 351,410 K in contrast with the sum of -454,030 K annual income. Company’s last quarter sales were recorded 90,700 K and last quarter income was -245,110 K.


On What Basis Did Swvl Holdings Corp (SWVL) Stock Rise 47% Pre-Hours?

When last checked, Swvl Holdings Corp. (Nasdaq: SWVL), a...

What Drove Organovo (ONVO) Stock Up 15% In After-Hour Session On Tuesday?

Shares of Organovo Holdings Inc. (Nasdaq: ONVO) were up...

Is There Any Reason As To Why The Zai Lab (ZLAB) Stock Expanded By 13%?

The biopharmaceutical business Zai Lab Limited (NASDAQ: ZLAB), which...



Don't miss

Did Anything Boost ObsEva (OBSV) Stock In Pre-Hours Trading?

Following an update, shares of ObsEva SA (NASD: OBSV)...

How Did The Kalera (KAL) Stock Rise 32% Pre-Hours?

At the time of the most recent check, shares...

Why Has Selina Hospitality (SLNA) Stock Increased In Extended Session On Friday?

The stock of Selina Hospitality PLC (NASD: SLNA), which...

Do You Know Why Evolv Technologies (EVLV) Stock Surged Nearly 10% Today?

Today's charts show Evolv Technologies Holdings Inc. (Nasdaq: EVLV)...

5 Best TaaS Stocks to Buy Right Now

TaaS stock refers to a financial asset sold by...

Investors finally get a glimpse of Skechers U.S.A. Inc. (SKX) volume hitting the figure of 1.67 million.

Skechers U.S.A. Inc. (NYSE: SKX) on January 27, 2023, started off the session at the price of $47.85, plunging -0.86% from the previous trading...

MetLife Inc. (MET) volume exceeds 2.49 million: A new investment opportunity for investors

January 27, 2023, MetLife Inc. (NYSE: MET) trading session started at the price of $72.11, that was -0.25% drop from the session before. During...

Truist Financial Corporation (TFC) volume exceeds 4.15 million: A new investment opportunity for investors

On January 27, 2023, Truist Financial Corporation (NYSE: TFC) opened at $48.91, lower -0.04% from the last session. During the day, the shares moved...


Please enter your comment!
Please enter your name here